In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens

Journal of Laryngology and Otology

Volumn 123, Issue 9, 2009, Pages 978-981

  Yenisehirli G ^a   Bulut, Y ^a   Guven M ^a   Gunday E ^a  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

Antifungal Agents; Fungus Diseases; Otitis Externa

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; CANDIDA ALBICANS; DRUG POTENCY; EPSILOMETER TEST; EXTERNAL OTITIS; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; OTOMYCOSIS; SPECIES;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA ALBICANS; CANDIDIASIS; COLONY COUNT, MICROBIAL; EAR DISEASES; FLUCONAZOLE; HUMANS; ITRACONAZOLE; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 70450177300     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215109005489     Document Type: Article

References (22)

1. Kaur R, Mittal N, Kakkar M, Aggarwal AK, Mathur MD. Otomycosis: A clinicomycologic study. Ear Nose Throat J 2000;79:606-609
2. Lucente FE. Fungal infections of the external ear. Otolaryngol Clin North Am 1993;26:995-1006
3. Vennewald I, Wollina U. Cutaneous infections due to opportunistic molds: uncommon presentations. Clin Dermatol 2005;23:565-571
4. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997;41:1364-1368
5. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40:401-414
6. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8
7. Kombila M, Gomez de Diaz M, de Bievre C, Crepet G, Debrie JC, Belembaogo E et al. Fungal otitis in Libreville. Study of 83 cases. Bull Soc Pathol Exot Filiales 1989;82: 201-207
8. Ozcan KM, Ozcan M, Karaarslan A, Karaarslan F. Otomycosis in Turkey: predisposing factors, aetiology and therapy. J Laryngol Otol 2003;117:39-42
9. Kaya AD, Kiraz N. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole. Mycoses 2007;50:447-450
10. Phillips P, Bryce G, Shepherd J, Mintz D. Invasive external otitis caused by Aspergillus. Rev Infect Dis 1990;12:277-281
11. Stodulski D, Kowalska B, Stankiewicz C. Otogenic skull base osteomyelitis caused by invasive fungal infection. Case report and literature review. Eur Arch Otorhinolaryngol 2006;263:1070-1076
12. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS Document M38-A. Villanova, Pennsylvania: Clinical and Laboratory Standards Institute, 2002
13. Espinel-Ingroff A, Rezusta A. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol 2002;40:2101-2107
14. Pfaller JB, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. In vitro susceptibility testing of Aspergillus spp.: comparison of E-test and reference microdilution methods for determining voriconazole and itraconazole MICs. J Clin Microbiol 2003;41:1126-1129
15. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and E-test methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 2003;41:1440-1446
16. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12: 40-79
17. Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46:1032-1037
18. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 2006;44:1782-1787
19. Verweij PE, Te Dorsthorst DT, Rijs AJ, De Vries-Hospers HG, Meis JF. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 2002;40:2648-2650
20. Dannaoui E, Persat F, Monier MF, Borel E, Piens MA, Picot S. In vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother 1999;44:553-555 (Pubitemid 29490629)
21. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 2005;43: 3807-3810
22. Mallié M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M et al. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using E-test: results of a French multicentre study. Int J Antimicrob Agents 2005;25:321-328